Close
  Indian J Med Microbiol
 

Figure 3: Timeline of the interventions and outcomes. AJCC: American Joint Committee on Cancer staging system, DFS: Disease-free survival, TTF: Time to treatment failure, PD: Progressive disease, PR: Partial remission, HPD: Hyperprogressive disease, CT: Computed tomography, PET: Positron-emission tomography, IHC: Immunohistochemistry, NGS: Next-generation sequencing, PD-L1: Programmed cell death ligand 1, MDM2: Murine double minute gene 2, CDK4: Cell cycle-dependent kinase 4, HER3: Human epidermal growth factor receptor 3, FRS2: Fibroblast growth factor receptor substrate 2, EZH2: Enhancer of Zeste Homolog 2

Figure 3: Timeline of the interventions and outcomes. AJCC: American Joint Committee on Cancer staging system, DFS: Disease-free survival, TTF: Time to treatment failure, PD: Progressive disease, PR: Partial remission, HPD: Hyperprogressive disease, CT: Computed tomography, PET: Positron-emission tomography, IHC: Immunohistochemistry, NGS: Next-generation sequencing, PD-L1: Programmed cell death ligand 1, <i>MDM2</i>: <i>Murine double minute gene 2</i>, <i>CDK4</i>: <i>Cell cycle-dependent kinase 4</i>, HER3: Human epidermal growth factor receptor 3, <i>FRS2</i>: <i>Fibroblast growth factor receptor substrate 2</i>, <i>EZH2</i>: <i>Enhancer of Zeste Homolog 2</i>